Clinical Trial: NCT06149247
HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Status:
COMPLETEDPhase:
Phase 2| Lead Sponsor: | Soligenix |
| Information Provided By: | Soligenix |
| Last Update Posted: | 2025-08-20 |
Study Overview
Brief Summary
The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
Official Title
Pilot Study of HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Conditions
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Intervention / Treatment
- Drug: Hypericin
- Drug: Mechlorethamine Topical Gel
Other Study ID Numbers
- HPN-CTCL-04
Start Date (Actual)
2023-12-05
Primary Completion Date (Actual)
2024-05-31
Study Completion Date (Actual)
2024-06-27
Enrollment (Actual)
10
Study Type
Interventional
Phase
Phase 2
| Lead Sponsor: | Soligenix |
| Information Provided By: | Soligenix |
| Last Update Posted: | 2025-08-20 |
Study Overview
Brief Summary
The objective of this clinical study is to compare the safety and effectiveness of Valchlor versus HyBryte following 12 weeks of treatment.
Official Title
Pilot Study of HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL
Conditions
Cutaneous T-Cell Lymphoma/Mycosis Fungoides
Intervention / Treatment
- Drug: Hypericin
- Drug: Mechlorethamine Topical Gel
Other Study ID Numbers
- HPN-CTCL-04
Start Date (Actual)
2023-12-05
Primary Completion Date (Actual)
2024-05-31
Study Completion Date (Actual)
2024-06-27
Enrollment (Actual)
10
Study Type
Interventional
Phase
Phase 2